Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johann S de Bono

Showing results (1-10 of 391) with videos related to

Pageof 40
Sort By:
European Urology|August 22, 2016
Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033Johann S de Bono
Nature Reviews. Urology|November 24, 2018
Immunotherapy for lethal prostate cancerPasquale Rescigno, Johann S de Bono
Nature Reviews. Urology|September 4, 2009
Prostate cancer: PSA as an intermediate end point in clinical trialsGerhardt Attard, Johann S de Bono
European Urology|November 21, 2015
The Ongoing Challenges of Targeting the Androgen ReceptorMichael Kolinsky, Johann S de Bono
The New England Journal of Medicine|February 8, 2018
Metastatic Prostate CancerOliver Sartor, Johann S de Bono
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Interrogating the Cancer Genome to Deliver More Precise Cancer CareJoaquin Mateo, Johann S de Bono
The New England Journal of Medicine|April 26, 2018
Metastatic Prostate CancerOliver Sartor, Johann S de Bono
Cancer Cell|July 15, 2020
Prostate Cancer 2020: "The Times They Are a'Changing"Alec Paschalis, Johann S de Bono
Current Problems in Cancer|June 7, 2017
Targeting DNA damage response systems to impact cancer careJoaquin Mateo, Johann S de Bono
European Urology|June 1, 2016
Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31Pasquale Rescigno, Johann S de Bono
Pageof 40

Showing results (1-10 of 391) with videos related to

Sort By:
Pageof 40
European Urology|August 22, 2016
Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033Johann S de Bono
Nature Reviews. Urology|November 24, 2018
Immunotherapy for lethal prostate cancerPasquale Rescigno, Johann S de Bono
Nature Reviews. Urology|September 4, 2009
Prostate cancer: PSA as an intermediate end point in clinical trialsGerhardt Attard, Johann S de Bono
European Urology|November 21, 2015
The Ongoing Challenges of Targeting the Androgen ReceptorMichael Kolinsky, Johann S de Bono
The New England Journal of Medicine|February 8, 2018
Metastatic Prostate CancerOliver Sartor, Johann S de Bono
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Interrogating the Cancer Genome to Deliver More Precise Cancer CareJoaquin Mateo, Johann S de Bono
The New England Journal of Medicine|April 26, 2018
Metastatic Prostate CancerOliver Sartor, Johann S de Bono
Cancer Cell|July 15, 2020
Prostate Cancer 2020: "The Times They Are a'Changing"Alec Paschalis, Johann S de Bono
Current Problems in Cancer|June 7, 2017
Targeting DNA damage response systems to impact cancer careJoaquin Mateo, Johann S de Bono
European Urology|June 1, 2016
Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31Pasquale Rescigno, Johann S de Bono
Pageof 40